Stem cell co Mesoblast reports PhIII trial success in children with GVHD – Endpoints News
Endpoints News |
Stem cell co Mesoblast reports PhIII trial success in children with GVHD
Endpoints News The company, called Mesoblast $MESO, was testing its allogeneic mesenchymal stem cell product called remestemcel-L. The off-the-shelf therapy is meant to treat Graft Versus Host Disease, a condition that often arises in blood cancer patients who’ve had … |
FierceBiotech |
Gilead, Sangamo strike $3B off-the-shelf CAR–T deal
FierceBiotech Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR–T therapies to cement its position as a long-term … Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR–T BoostXconomy Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy PartnershipGenetic Engineering & Biotechnology News Gilead is making a $3.1 billion bet on an experimental editing technology for cancer treatmentsBusiness Insider Endpoints News –San Francisco Business Times –pharmaphorum all 58 news articles » |
FierceBiotech |
Gilead, Sangamo strike $3B off-the-shelf CAR–T deal
FierceBiotech Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR–T therapies to cement its position as a long-term … Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR–T BoostXconomy Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy PartnershipGenetic Engineering & Biotechnology News Gilead is making a $3.1 billion bet on an experimental editing technology for cancer treatmentsBusiness Insider Endpoints News –San Francisco Business Times –pharmaphorum all 58 news articles » |
Xconomy |
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR–T Boost
Xconomy The alliance continues Gilead’s dealmaking spree in CAR–T, a method of cancer treatment in which a patient’s immune cells are removed, modified, and re-infused into the body to find and kill cancer. Gilead’s run began when it paid nearly $12 billion … Gilead and Sangamo deal shows that CRISPR still has competitionChemical & Engineering News Sangamo Inks $3B Deal with CAR T Leader Gileadhcanews.com How Gilead Sciences Is Betting Big on Gene EditingMotley Fool Genetic Engineering & Biotechnology News –Business Insider –Zacks –Zacks all 101 news articles » |
Genetic Literacy Project |
Viewpoint: CRISPR is for more than just human gene editing
Genetic Literacy Project If you’ve ever heard of CRISPR, it has most likely been in the context of human gene editing. … CRISPR itself threatens to be swept up in the controversy, forever branded as something that might be too dangerous to ever use. As a scientist who uses … |
Genetic Literacy Project |
Viewpoint: CRISPR is for more than just human gene editing
Genetic Literacy Project If you’ve ever heard of CRISPR, it has most likely been in the context of human gene editing. … CRISPR itself threatens to be swept up in the controversy, forever branded as something that might be too dangerous to ever use. As a scientist who uses … |
Genetic Literacy Project |
Africa could become a world agricultural leader in CRISPR and other new breeding techniques (NBTs)
Genetic Literacy Project She believes the arguments and controversies arising from the use of gene editing and synthetic biology in plant breeding will continue to boil. But that won’t discourage agricultural scientists globally, as they strive to improve plant breeding. Dr … |
Genetic Literacy Project |
Africa could become a world agricultural leader in CRISPR and other new breeding techniques (NBTs)
Genetic Literacy Project She believes the arguments and controversies arising from the use of gene editing and synthetic biology in plant breeding will continue to boil. But that won’t discourage agricultural scientists globally, as they strive to improve plant breeding. Dr … |